We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients.
- Authors
KARATAŞ, Ayşe; MALKAN, Ümit Yavuz; VELET, Mustafa; DEMİROĞLU, Haluk; BÜYÜKAŞIK, Yahya; DİZMAN, Gülçin TELLİ; İNKAYA, Ahmet Çağkan; ERDOĞDU, Batuhan; ÇINAR, Olgu Erkin; ALADAĞ, Elifcan; AKSU, Salih; HAZNEDAROĞLU, İbrahim Celalettin; ÖZCEBE, Osman; SAYINALP, Nilgün; GÖKER, Hakan
- Abstract
Background/aim: The disease caused by SARS-CoV-2 was named as COVID-19. There is as yet insufficient information about the effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in patients who had undergone HSCT. Materials and methods: We analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death rates, overall survival, and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively. Results: 57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild, moderate, and severe COVID-19 or critical illness, respectively. Overall, 45.5% were hospitalized, 12.1% required intensive care, and 9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic malignancy, and 4.2% in patients without active hematologic malignancy. Conclusion: It can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to ones that are not in remission. Further studies with larger group patients are needed in order to delineate the effects of COVID-19 on HSCT patients.
- Subjects
HEMATOPOIETIC stem cell transplantation; COVID-19; OVERALL survival; SARS-CoV-2; DEATH rate
- Publication
Turkish Journal of Medical Sciences, 2021, Vol 51, Issue 4, p1047
- ISSN
1300-0144
- Publication type
Article
- DOI
10.3906/sag-2103-72